Issues in hypertriglyceridemic pancreatitis: An update

John Scherer, Vijay Prem Singh, C. S. Pitchumoni, Dhiraj Yadav

Research output: Contribution to journalArticle

133 Citations (Scopus)

Abstract

Hypertriglyceridemia (HTG) is a well-established but underestimated cause of acute pancreatitis and recurrent acute pancreatitis. The clinical presentation of HTG-induced pancreatitis (HTG pancreatitis) is similar to other causes. Pancreatitis secondary to HTG is typically seen in the presence of one or more secondary factors (uncontrolled diabetes, alcoholism, medications, pregnancy) in a patient with an underlying common genetic abnormality of lipoprotein metabolism (familial combined hyperlipidemia or familial HTG). Less commonly, a patient with rare genetic abnormality (familial chylomicronemic syndrome) with or without an additional secondary factor is encountered. The risk of acute pancreatitis in patients with serum triglycerides >1000 and >2000 mg/dL is ∼5% and 10% to 20%, respectively. It is not clear whether HTG pancreatitis is more severe than when it is due to other causes. Clinical management of HTG pancreatitis is similar to that of other causes. Insulin infusion in diabetic patients with HTG can rapidly reduce triglyceride (TG) levels. Use of apheresis is still experimental and better designed studies are needed to clarify its role in the management of HTG pancreatitis. Diet, lifestyle changes, and control of secondary factors are key to the treatment, and medications are useful adjuncts to the long-term management of TG levels. Control of TG levels to 500 mg/dL or less can effectively prevent recurrences of pancreatitis.

Original languageEnglish (US)
Pages (from-to)195-203
Number of pages9
JournalJournal of Clinical Gastroenterology
Volume48
Issue number3
DOIs
StatePublished - Mar 2014

Fingerprint

Pancreatitis
Hypertriglyceridemia
Triglycerides
Familial Combined Hyperlipidemia
Hyperlipoproteinemia Type IV
Blood Component Removal
Alcoholism
Lipoproteins
Life Style
Insulin
Diet
Recurrence
Pregnancy
Serum

Keywords

  • Hyperlipidemia
  • Hypertriglyceridemia
  • Pancreatitis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Issues in hypertriglyceridemic pancreatitis : An update. / Scherer, John; Singh, Vijay Prem; Pitchumoni, C. S.; Yadav, Dhiraj.

In: Journal of Clinical Gastroenterology, Vol. 48, No. 3, 03.2014, p. 195-203.

Research output: Contribution to journalArticle

Scherer, John ; Singh, Vijay Prem ; Pitchumoni, C. S. ; Yadav, Dhiraj. / Issues in hypertriglyceridemic pancreatitis : An update. In: Journal of Clinical Gastroenterology. 2014 ; Vol. 48, No. 3. pp. 195-203.
@article{c954190066b84dd48e47fde6753b1227,
title = "Issues in hypertriglyceridemic pancreatitis: An update",
abstract = "Hypertriglyceridemia (HTG) is a well-established but underestimated cause of acute pancreatitis and recurrent acute pancreatitis. The clinical presentation of HTG-induced pancreatitis (HTG pancreatitis) is similar to other causes. Pancreatitis secondary to HTG is typically seen in the presence of one or more secondary factors (uncontrolled diabetes, alcoholism, medications, pregnancy) in a patient with an underlying common genetic abnormality of lipoprotein metabolism (familial combined hyperlipidemia or familial HTG). Less commonly, a patient with rare genetic abnormality (familial chylomicronemic syndrome) with or without an additional secondary factor is encountered. The risk of acute pancreatitis in patients with serum triglycerides >1000 and >2000 mg/dL is ∼5{\%} and 10{\%} to 20{\%}, respectively. It is not clear whether HTG pancreatitis is more severe than when it is due to other causes. Clinical management of HTG pancreatitis is similar to that of other causes. Insulin infusion in diabetic patients with HTG can rapidly reduce triglyceride (TG) levels. Use of apheresis is still experimental and better designed studies are needed to clarify its role in the management of HTG pancreatitis. Diet, lifestyle changes, and control of secondary factors are key to the treatment, and medications are useful adjuncts to the long-term management of TG levels. Control of TG levels to 500 mg/dL or less can effectively prevent recurrences of pancreatitis.",
keywords = "Hyperlipidemia, Hypertriglyceridemia, Pancreatitis",
author = "John Scherer and Singh, {Vijay Prem} and Pitchumoni, {C. S.} and Dhiraj Yadav",
year = "2014",
month = "3",
doi = "10.1097/01.mcg.0000436438.60145.5a",
language = "English (US)",
volume = "48",
pages = "195--203",
journal = "Journal of Clinical Gastroenterology",
issn = "0192-0790",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Issues in hypertriglyceridemic pancreatitis

T2 - An update

AU - Scherer, John

AU - Singh, Vijay Prem

AU - Pitchumoni, C. S.

AU - Yadav, Dhiraj

PY - 2014/3

Y1 - 2014/3

N2 - Hypertriglyceridemia (HTG) is a well-established but underestimated cause of acute pancreatitis and recurrent acute pancreatitis. The clinical presentation of HTG-induced pancreatitis (HTG pancreatitis) is similar to other causes. Pancreatitis secondary to HTG is typically seen in the presence of one or more secondary factors (uncontrolled diabetes, alcoholism, medications, pregnancy) in a patient with an underlying common genetic abnormality of lipoprotein metabolism (familial combined hyperlipidemia or familial HTG). Less commonly, a patient with rare genetic abnormality (familial chylomicronemic syndrome) with or without an additional secondary factor is encountered. The risk of acute pancreatitis in patients with serum triglycerides >1000 and >2000 mg/dL is ∼5% and 10% to 20%, respectively. It is not clear whether HTG pancreatitis is more severe than when it is due to other causes. Clinical management of HTG pancreatitis is similar to that of other causes. Insulin infusion in diabetic patients with HTG can rapidly reduce triglyceride (TG) levels. Use of apheresis is still experimental and better designed studies are needed to clarify its role in the management of HTG pancreatitis. Diet, lifestyle changes, and control of secondary factors are key to the treatment, and medications are useful adjuncts to the long-term management of TG levels. Control of TG levels to 500 mg/dL or less can effectively prevent recurrences of pancreatitis.

AB - Hypertriglyceridemia (HTG) is a well-established but underestimated cause of acute pancreatitis and recurrent acute pancreatitis. The clinical presentation of HTG-induced pancreatitis (HTG pancreatitis) is similar to other causes. Pancreatitis secondary to HTG is typically seen in the presence of one or more secondary factors (uncontrolled diabetes, alcoholism, medications, pregnancy) in a patient with an underlying common genetic abnormality of lipoprotein metabolism (familial combined hyperlipidemia or familial HTG). Less commonly, a patient with rare genetic abnormality (familial chylomicronemic syndrome) with or without an additional secondary factor is encountered. The risk of acute pancreatitis in patients with serum triglycerides >1000 and >2000 mg/dL is ∼5% and 10% to 20%, respectively. It is not clear whether HTG pancreatitis is more severe than when it is due to other causes. Clinical management of HTG pancreatitis is similar to that of other causes. Insulin infusion in diabetic patients with HTG can rapidly reduce triglyceride (TG) levels. Use of apheresis is still experimental and better designed studies are needed to clarify its role in the management of HTG pancreatitis. Diet, lifestyle changes, and control of secondary factors are key to the treatment, and medications are useful adjuncts to the long-term management of TG levels. Control of TG levels to 500 mg/dL or less can effectively prevent recurrences of pancreatitis.

KW - Hyperlipidemia

KW - Hypertriglyceridemia

KW - Pancreatitis

UR - http://www.scopus.com/inward/record.url?scp=84894077068&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894077068&partnerID=8YFLogxK

U2 - 10.1097/01.mcg.0000436438.60145.5a

DO - 10.1097/01.mcg.0000436438.60145.5a

M3 - Article

C2 - 24172179

AN - SCOPUS:84894077068

VL - 48

SP - 195

EP - 203

JO - Journal of Clinical Gastroenterology

JF - Journal of Clinical Gastroenterology

SN - 0192-0790

IS - 3

ER -